Gong Kan

20. Cancer Discovery、PNAS、Cancer Research SCI 100, 3, 1.,. 、 、. “ ”、 “ ”、 “ ”、 、 、 、 、 、 、 、 VHL 、《 —— 》. 1. Xie, H., Zhou, J., Liu, X., Xu, Y., Hepperla, J. A.,... & Gong, K.*, Zhang, Q.* (2022). USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer. PNAS, 119(36): e2119854119. (IF=11.1) 2. Zhou, J., & Gong, K.* (2022). Belzutifan: a novel therapy for von Hippel–Lindau disease. Nature Reviews Nephrology, 1-2. (IF= 42.439) 3. Hu, L., Xie, H., Liu, X., Potjewyd, F., James, L. I., Wilkerson, E. M.,... & Gong, K.*, Zhang, Q.* (2019). TBK1 is a Synthetic Lethal Target in Cancer with VHL Loss. Cancer Discovery, 10(3): 460-475. (IF= 38.272) 4. Ning, X. H., Zhang, N., Li, T., Wu, P. J., Wang, X., Li, X. Y.,... & Gong, K.* (2014). Telomere shortening is associated with genetic anticipation in Chinese Von Hippel–Lindau disease families. Cancer research, 74(14), 3802-3809. (IF= 13.312) 5. Liu, S. J., Wang, J. Y., Peng, S. H., Li, T., Ning, X. H., Hong, B. A.,... & Gong, K.* (2018). Genotype and phenotype correlation in von Hippel–Lindau disease based on alteration of the HIF-α binding site in VHL protein. Genetics in Medicine, 20(10), 1266. (IF= 8.864) 1.2017 “ ” 2.2016 “ ” 3.2015 4.2014 5.2012 6.2011 7.2010 “ ”